| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Analytical methods for the characterization and quality control of pharmaceutical peptides and proteins, using erythropoietin as an example
|
Gilg, David
|
|
1996
|
71 |
6 |
p. 383-394
12 p.
|
artikel
|
| 2 |
Author index
|
|
|
1996
|
71 |
6 |
p. 463-464
2 p.
|
artikel
|
| 3 |
Contents to volume 71
|
|
|
1996
|
71 |
6 |
p. 465-468
4 p.
|
artikel
|
| 4 |
Degradation pathways, analytical characterization and formulation strategies of a peptide and a protein calcitonine and human growth hormone in comparison
|
Cholewinski, Malgorzata
|
|
1996
|
71 |
6 |
p. 405-419
15 p.
|
artikel
|
| 5 |
Keyword index
|
|
|
1996
|
71 |
6 |
p. 459-461
3 p.
|
artikel
|
| 6 |
Quality assurance after process changes of the production of a therapeutic antibody
|
Brass, Johann M.
|
|
1996
|
71 |
6 |
p. 395-403
9 p.
|
artikel
|
| 7 |
Quality assurance for biopharmaceuticals: An overview of regulations, methods and problems
|
Müller, Kristian M.
|
|
1996
|
71 |
6 |
p. 421-438
18 p.
|
artikel
|
| 8 |
Quality assurance in the development, production, control and registration of peptides and proteins
|
|
|
1996
|
71 |
6 |
p. 381-
1 p.
|
artikel
|
| 9 |
Requirements for the quality control of chemically synthesized peptides and biotechnologically produced proteins
|
Bichsel, Verena E.
|
|
1996
|
71 |
6 |
p. 439-446
8 p.
|
artikel
|
| 10 |
Special considerations concerning regulatory requirements and drug development for peptides and biotech products in the EU
|
Braun, Andrea
|
|
1996
|
71 |
6 |
p. 447-458
12 p.
|
artikel
|
Tijdschrift beschrijving